「国创上头条」既有CD47,又有PD-L1,盘点最新5款获授权引进中国的创新药( 三 )


[3]信达生物与Alector达成合作 在中国开发和商业化抗SIRP-alpha抗体. Retrieved March 26 , 2020, from https://www.prnasia.com/story/275928-1.shtml
[4]Laekna Acquires Exclusive Global Rights to Clinical-Stage Cancer Asset. Retrieved March 24 , 2020, from https://www.businesswire.com/news/home/20200324005279/en/Laekna-Acquires-Exclusive-Global-Rights-Clinical-Stage-Cancer?from=singlemessage&isappinstalled=0
【「国创上头条」既有CD47,又有PD-L1,盘点最新5款获授权引进中国的创新药】[5]Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China. Retrieved Mar 19 2020 from https://www.tarvedatx.com/3-19-20-tarveda-therapeutics-and-sciclone-pharmaceuticals-international-establish-licensing-agreement-for-pen-866-in-greater-china